BAB VI KESIMPULAN DAN SARAN
6.2 Saran
1. Penelitian lebih lanjut dengan sampel yang besar dan dengan dosis yang lebih besar dari 80 mg pada individu yang mengkonsumsi obat anti trombosit dengan metodologi yang lebih baik di masa yang akan datang.
2. Dibutuhkan studi lebih lanjut tentang penderita DM dengan stroke iskemik akut bila diberikan terapi aspirin.
3. Perlu dilakukan studi lebih lanjut yang mengevaluasi luasnya infark dengan agregasi trombosit dan tingkat perbaikan klinik setelah terapi aspirin pada pasien stroke iskemik kasus baru.
DAFTAR PUSTAKA
1. Hinkle JL, Guanci M. Acute Ischemic Stroke Review. J Neuroscience Nurs. 2007;39:285-93.
2. Hariyono T. Tinjauan Pustaka Hipertensi dan Stroke. SMF Ilmu Penyakit Saraf RSUD Banyumas.
3. Japardi I. Patofisiologi Stroke Infark Akibat Tromboemboli. Bagian Bedah Saraf Fakultas Kedokteran Universitas Sumatera Utara. 2002:1-9.
4. Rambe AS. Stroke : Sekilas tentang definisi, penyebab, efek, dan faktor risiko. Departemen Neurologi FK-USU
5. Caplan LR. Classification of stroke. UpToDate 2009. Available from : http://
6. Setiabudy RD. Hemostasis dan Trombosis. Balai Penerbit Fakultas
Kedokteran Universitas Indonesia. 2007:34-84.
7. Fateh S, Htun P, Tomandi B et al. Hyperresponsiveness of platelets in ischemic stroke. Thromb Haemost. 2007;97:974-8.
8. Hasan R. Penilaian Kemampuan Antiagregrasi Trombosit Asam Asetil
Salisilat (Aspirin) Dosis 80 mg dan Dosis 320 mg pada Penderita Penyakit Jantung Koroner. Bagian Ilmu Penyakit Dalam Fakultas Kedoketeran Universitas Sumatera Utara 1998.
9. Dewi J, Hernowati TE. Hubungan Persentase Agregrasi Trombosit dengan
Lamanya Konsumsi Aspirin pada Penderita Aterosklerosis di Poli jantung RSU Dr. Saiful Anwar Malang. Medicinus. 2008;21:63-5.
10. Smith NM, Pathansali R, Bath PMW. Platelets and Stroke. Vascular
Medicine. 1999;4:165-172.
11. Jurk K, Kehrel BE. Platelets : Physiology and Biochemistry. Seminars in thrombosis and hemostasis. 2005;31:381-90.
12. Abrams CS. Platelet biology. UpToDate 2009. Available from : http://
13. Rivera J, Lozano ML, Navarro L, Vicente V. Platelet receptor and signaling in the dynamics of thrombus formation. Haematologica. 2009;94:700-9.
14. Ofosu FA. The Blood Platelet as a Model for Regulating Blood Coagulation on Cell Surface and Its Consequences. Biochemistry. 2002;67:47-55.
15. Kuter DJ. Megakaryocyte biology and the production of platelet. UpToDate 2009. Available from : http://
16. Leung LLK. Overview of hemostasis. UpToDate 2009. Available from :
http://
17. Suharti C. Dasar-dasar Hemostasis. Dalam : Sudoyo AW, Setiyohadi B,
Alwi I dkk., eds. Buku Ajar Ilmu Penyakit Dalam. Pusat Penerbitan Ilmu Penyakit Dalam. 2009:1293-300.
18. Furie B. Pathogenesis of thrombosis. Haematology. 2009:255-8.
19. Nachman RL, Rafii S. Platelets, Petechiae and Preservation of the Vascular Wall. N Eng J Med. 2008;18:1261-70.
20. Bakta IM. Thrombosis dan Usia Lanjut. J Penyakit Dalam. 2007;8:148-59. 21. Tambunan KL. Patogenesis Trombosis. Dalam : Sudoyo AW, Setiyohadi B,
Alwi I dkk., eds. Buku Ajar Ilmu Penyakit Dalam. Pusat Penerbitan Ilmu Penyakit Dalam. 2009:1301-6.
22. Sjahrir H. Stroke Iskemik. Yandira Agung Medan. 2003:1-35.
23. Aliah A, Widjaya D. Faktor Risiko Strok pada Beberapa Rumah Sakit di Makassar (Kurun Januari – September 2000). Jurnal Medika Nusantara. 2004;25:1-4.
24. Widjaya D. Hipertensi dan Stroke. Cermin Dunia Kedokteran. 1994:24-33. 25. Makino Y, Kawano Y, Minami J et al. Risk of Stroke in Relation to Level of
Blood Pressure and other Risk Factors in Treated Hypertensive Patients. Stroke. 2000;31:48-52.
26. Lawes CM, Bennett DA, Feigin VL et al. Blood Pressure and Stroke : An Overview of Published Reviews. Stroke. 2004;35:776-85.
27. Bowman TS, Sesso HD, Kurth T et al. Cholesterol and the Risk of Ischemic Stroke. Stroke. 2003;34:2930-4.
28. Espinosa EP, Murad J, Khasawneh. Aspirin : Pharmacology and Clinical Applications. Hindawi Publishing Corporation. 2011;2012:1-15.
29. Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost.
30. Furie KL, Kasner SE, Adams RJ et al. Guidelines for the Prevention os Stroke in Patients With Stroke or Transient Ischemic Attack : A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011;42:227-76.
31. Chen ZM, Sandercock P, Pan HC et al. Indications for Early Aspirin Use in Acute Ischemic Stroke : A Combined Analysis of 40 000 Randomized Patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke. 2000;31:1240-9.
32. Oliveira J, Koroshetz WJ. Antithrombotic treatment of acute ischemic stroke. UpToDate 2009. Available from : http://
33. Cucchiara B, Messe SR. Antiplatelet therapy for secondary prevention of stroke. UpToDate 2009. Available from : http://
34. McCabe DJ, Brown MM. Prevention of ischaemic stroke-antiplatelets.
British Medical Bulletin. 2000;56:510-25.
35. Weksler BB, Kent JL, Rudolph D et al. Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia. Stroke. 1985;16:5-9.
36. Hirsh J. Progress Review : The Relationship Between Dose of Aspirin, Side- Effects and Antithrombotic Effectiveness. Stroke. 1985;16:1-4.
37. Patrono C, Rodriguez LA, Landolfi R. Low-Dose Aspirin for the Prevention of Atherothrombosis. N Eng J Med. 2005;335:2373-83.
38. Harrison P. Platelet function testing. UpToDate 2009. Available from : http://
39. Wirawan R. Nilai Rujukan Pemeriksaan Agregasi Trombosit dengan
Adenosin Difosfat pada Orang Indonesia Dewasa Normal dj Jakarta. Majalah Kedokteran Indonesia. 2007;57:212-9.
40. Harrison P. Platelet function analysis. Blood Reviews. 2005;19:111-123. 41. Tumbelaka AR, Riono P, Sastroasmoro S, Wirjodiarjo M, Pudjiastuti P,
Firman K. Pemilihan uji hipotesis. Dalam : Sastroasmoro S., ed. Dasar-dasar Metodologi Penelitian Klinis. Sagung Seto. 2010:279-300.
42. Fazio C, Agnoli A, Meyer JS. Summary of the International Round Table Conference on Platelet Aggregation in the Pathogenesis of Cerebrovascular Disorders. Stroke. 1975;6:239-44.
43. Donnell CJ, Larson MG, Feng D et al. Genetic and Environmental
Contribution to Platelet Aggregation : The Framingham Heart Study. Circulation. 2001;3051-6.
44. Albers GW, Amarenco P, Easton JD et al. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Chest. 2001;119:300-20.
45. Mousa SA. Antiplatelet therapies : from aspirin to GPIIb/IIIa-receptor antagonists and beyond. DDT. 1999;4:552-61.
46. Bednar MM, Gross CE. Antiplatelet Therapy in Acute Cerebral Ischemia. Stroke. 1999;30:887-93.
47. Wilterdink JL, Bandixen B, Adams HP et al. Effect of Prior Aspirin Use on Stroke Severity In Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke. 2001;32:2836-40.
48. Grau AJ, Reiners S, Lichy C et al. Platelet Function Under Aspirin,
Clopidogrel, and Both After Ischemic Stroke : A Case-Crossover Study*Synergistic Antiplatelet effects of Clopidogrel and Aspirin Detected With the PFA-100 in Stroke Patients. Stroke. 2003;34:849-54.
49. Bornstein NM. Antiplatelet Aggregant Therapy to Prevent Stroke. In : Marc Fisher ed. Stroke Therapy. Butterworth Heinemann New Delhi. 2001:159- 69.
50. Cox DC, Maree AO, Dooley M et al. Effect of Enteric Coated on
Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers. Stroke. 2006;37:2153-8.
51. A Swedish Cooperative Study. High-Dose Acetylsalicylic Acid After
Cerebral Infarction. Stroke. 1987;18:325-34.
52. Mardikar H, Deo D, Deshpande N et al. Variability in Platelet Response to A Single Daily Dose of 150 mg Enteric Coated Aspirin in A High Risk Population. JAPI. 2008;56:321-4.
53. Meyer DM, Albright KC, Allison TA. LOAD : A Pilot Study of the Safety of Loading of Aspirin and Clopidogrel in Acute Ischemic Stroke and
Transient Ischemic Attack. Journal of Stroke and Cerebrovascular Diseases. 2008;26-9.
54. Meves SH, Neubauer H, Overbeck U, Endres HG. Is there an ideal way to initiate antiplatelet therapy with aspirin? A crossover study on healthy volunteers evaluating different dosing schemes with whole blood aggregometry.BMC Research. 2011;4:1-8.
55. Biller J. Antiplatelet therapy in ischemic stroke : variability in clinical trials and its impact on choosing the appropriate therapy. Journal of the Neurological Sciences. 2009;284:1-9.
56. Coull BM, Williams LS, Goldstein LB et al. Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke : Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association. Stroke. 2002;33:1934-42.
57. Suharti C, Lumbantobing M, Suyono. Faktor-faktor protrombotik pada
diabetes mellitus. Dalam : Darmono, Suhartono T, Pemayun TGD, Padmomartono FS., eds. Diabetes Mellitus Ditinjau dari Berbagai Aspek Penyakit Dalam. Badan Penerbit Universitas Diponegoro. 2007:63-72.
58. Pengurus Besar Perkumpulan Endokrinologi Indonesia. Petunjuk Praktis Penatalaksanaan Dislipidemia. 2004:1-19.
59. Lakhan SE, Bagchi S, Hofer M. Statins and Clinical Outcome of Acute
Ischemic Stroke : a Systematic Review. International Archives of Medicine.2010;22:1-7.
60. Tohgi H, Konno S, Tamura K et al. Effects of low to high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke. 1992;23:1400-3.
61. Tohgi H, Tamura K, Kimura B. Individual Variation in Platelet
Aggregability and Serum Thromboxane B2 Concentrations After Low-Dose
Aspirin. Stroke. 1988;19:700-3.
62. Spranger M, Aspey BS, Harrison MJ. Sex difference in antithrombotic effect of aspirin. Stroke. 1989;20:34-37.
63. Michos ED, Ardehali R, Blumenthal RS, Lange RA, Ardehali H. Aspirin
64. Navarro JC, Lao AY, Yumul MP, Araullo LC, Lokin JK, Baroque AC. Aspirin resistance among patients with recurrent non-cardioembolic stroke detected by rapid platelet function analyzer. Neurology Asia. 2007;12:89-95. 65. Krasopoulos G, Beattie WS, Elliot RF, Burchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity : Systematic review and meta-analysis. BMJ Research. 2007:1-9.
66. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet Effect of Aspirin in Patients with Cerebrovascular Disease. Stroke. 2004;35:175-8.
67. Uchiyama S, Takeuchi M, Osawa M et al. Platelet function test in
thrombotic cerebrovascular disorders. Stroke. 1983;14:511-7.
68. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA,
Diodati JG. A comparison of six major platelet fuction test to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. European Heart Journal. 2007;28:1702-8.
69. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative Review : Aspirin Resistance and Its Clinical implications. Ann Intern Med. 2005;142:370-80. 70. Mehta JL, Mohandas B. Aspirin resistance : Fact or fiction? A point of view.
World Journal of Cardiology. 2010;2:280-8.
71. Cattaneo M. Laboratory detection of ‘aspirin resistance’ : what test should we use (if any)?. European Heart Journal Access. 2007:1-3.
72. Hankey HJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-17. 73. Husted S. Evidence-based prescribing and adherence to antiplatelet therapy-
How much difference do they make to patients with atherothrombosis? International Journal of Cardiology. 2009;134:150-9.
74. Biller J. Antiplatelet therapy in ischemic stroke : Variability in clinical trials and its impact on choosing the appropriate therapy. Journal of the Neurological Sciences. 2009;284:1-9.
75. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga P, Violi F. Inhibition of platelet aggregation by aspirin progesively decreases in long- term treated patients. JACC. 2004;43:979-84.
76. Maulaz AB, Bezerra DC, Michel P et al. Effect of Discontinuing Aspirin Therapy on the Risk of Brain Ischemic Stroke. Arch Neurol. 2005;62:1217- 20.